Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Robbins

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2011
Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccineJoanna Kubler-Kielb, Evgeny Vinogradov, Teresa Lagergård, et al.
The Pediatric Infectious Disease Journal|August 13, 2003
Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old childrenJusten H Passwell, Shai Ashkenazi, Efrat Harlev, et al.
Vaccine|April 20, 2011
Mutant lipooligosaccharide-based conjugate vaccine demonstrates a broad-spectrum effectiveness against Moraxella catarrhalisDabin Ren, Shengqing Yu, Song Gao, et al.
Clinical and Vaccine Immunology : CVI|December 24, 2010
Evaluation of serum bactericidal antibody assays for Haemophilus influenzae serotype aNadine G Rouphael, Sarah Satola, Monica M Farley, et al.
Clinical and Vaccine Immunology : CVI|December 23, 2011
Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracisJoseph A Bellanti, Feng-Ying C Lin, Chiayung Chu, et al.
Vaccine|January 9, 2010
Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli childrenJusten H Passwell, Shai Ashkenazi, Yonit Banet-Levi, et al.
Vaccine|August 6, 2019
Erratum to 'Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children' [Vaccine 28 (2010) 2231-2235]Justen H Passwell, Shai Ashkenazi, Yonit Banet-Levi, et al.
Journal of Clinical Microbiology|July 10, 2004
Antigenic evidence of prevalence and diversity of Mycobacterium tuberculosis arabinomannanAharona Glatman-Freedman, Arturo Casadevall, Zongdong Dai, et al.
The New England Journal of Medicine|October 3, 2003
Persistent efficacy of Vi conjugate vaccine against typhoid fever in young childrenNgoc Lanh Mai, Van Bay Phan, Anh Ho Vo, et al.
Clinical and Vaccine Immunology : CVI|March 18, 2011
The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccinesVu Dinh Thiem, Feng-Ying C Lin, Do Gia Canh, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2011
Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccineJoanna Kubler-Kielb, Evgeny Vinogradov, Teresa Lagergård, et al.
The Pediatric Infectious Disease Journal|August 13, 2003
Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old childrenJusten H Passwell, Shai Ashkenazi, Efrat Harlev, et al.
Vaccine|April 20, 2011
Mutant lipooligosaccharide-based conjugate vaccine demonstrates a broad-spectrum effectiveness against Moraxella catarrhalisDabin Ren, Shengqing Yu, Song Gao, et al.
Clinical and Vaccine Immunology : CVI|December 24, 2010
Evaluation of serum bactericidal antibody assays for Haemophilus influenzae serotype aNadine G Rouphael, Sarah Satola, Monica M Farley, et al.
Clinical and Vaccine Immunology : CVI|December 23, 2011
Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracisJoseph A Bellanti, Feng-Ying C Lin, Chiayung Chu, et al.
Vaccine|January 9, 2010
Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli childrenJusten H Passwell, Shai Ashkenazi, Yonit Banet-Levi, et al.
Vaccine|August 6, 2019
Erratum to 'Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children' [Vaccine 28 (2010) 2231-2235]Justen H Passwell, Shai Ashkenazi, Yonit Banet-Levi, et al.
Journal of Clinical Microbiology|July 10, 2004
Antigenic evidence of prevalence and diversity of Mycobacterium tuberculosis arabinomannanAharona Glatman-Freedman, Arturo Casadevall, Zongdong Dai, et al.
The New England Journal of Medicine|October 3, 2003
Persistent efficacy of Vi conjugate vaccine against typhoid fever in young childrenNgoc Lanh Mai, Van Bay Phan, Anh Ho Vo, et al.
Clinical and Vaccine Immunology : CVI|March 18, 2011
The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccinesVu Dinh Thiem, Feng-Ying C Lin, Do Gia Canh, et al.
Pageof 6